News

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...
Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...